VENUS REMEDIES
|
VENUS REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 33.90 | 21.31 | 19.87 | 30.47 | 50.04 |
| CEPS(Rs) | 50.74 | 41.10 | 44.04 | 55.55 | 78.63 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 419.65 | 364.74 | 344.38 | 329.50 | 313.18 |
| Tax Rate(%) | 36.91 | 36.18 | 29.96 | -11.85 | -27.21 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.81 | 9.91 | 10.81 | 10.35 | 9.81 |
| EBIT Margin(%) | 11.10 | 7.44 | 6.85 | 6.15 | 11.23 |
| Pre Tax Margin(%) | 11.09 | 7.42 | 6.83 | 6.07 | 8.86 |
| PAT Margin (%) | 6.99 | 4.74 | 4.78 | 6.79 | 11.27 |
| Cash Profit Margin (%) | 10.47 | 9.13 | 10.60 | 12.37 | 17.70 |
| Performance Ratios | |||||
| ROA(%) | 6.75 | 4.64 | 4.50 | 7.18 | 10.30 |
| ROE(%) | 8.64 | 6.01 | 5.90 | 9.85 | 17.40 |
| ROCE(%) | 13.17 | 8.67 | 7.72 | 7.89 | 12.37 |
| Asset Turnover(x) | 0.97 | 0.98 | 0.94 | 1.06 | 0.91 |
| Sales/Fixed Asset(x) | 1.03 | 0.98 | 0.91 | 0.98 | 0.88 |
| Working Capital/Sales(x) | 2.05 | 2.15 | 2.31 | 3.24 | 4.01 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.97 | 1.02 | 1.09 | 1.02 | 1.13 |
| Receivable days | 54.28 | 47.69 | 37.87 | 21.48 | 20.89 |
| Inventory Days | 62.59 | 73.32 | 80.68 | 74.69 | 86.94 |
| Payable days | 69.91 | 53.52 | 55.69 | 57.31 | 57.86 |
| Valuation Parameters | |||||
| PER(x) | 8.84 | 15.31 | 8.15 | 8.82 | 5.49 |
| PCE(x) | 5.90 | 7.94 | 3.68 | 4.84 | 3.49 |
| Price/Book(x) | 0.71 | 0.89 | 0.47 | 0.82 | 0.88 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.50 | 0.68 | 0.37 | 0.59 | 0.65 |
| EV/Core EBITDA(x) | 3.81 | 5.75 | 2.90 | 5.00 | 4.89 |
| EV/EBIT(x) | 4.48 | 9.15 | 5.37 | 9.54 | 5.83 |
| EV/CE(x) | 0.57 | 0.77 | 0.41 | 0.61 | 0.65 |
| M Cap / Sales | 0.62 | 0.73 | 0.39 | 0.60 | 0.62 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.72 | 8.27 | -7.44 | 9.50 | 61.53 |
| Core EBITDA Growth(%) | 18.69 | 1.19 | -0.11 | -4.07 | 59.14 |
| EBIT Growth(%) | 60.70 | 17.58 | 3.14 | -40.09 | 1,061.31 |
| PAT Growth(%) | 59.05 | 7.25 | -34.77 | -34.07 | 717.70 |
| EPS Growth(%) | 59.05 | 7.25 | -34.77 | -39.12 | 717.70 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.08 | 0.09 | 0.10 | 0.13 |
| Current Ratio(x) | 3.31 | 4.53 | 3.91 | 3.00 | 2.40 |
| Quick Ratio(x) | 2.58 | 2.99 | 2.46 | 1.64 | 1.17 |
| Interest Cover(x) | 1,099.26 | 477.45 | 322.44 | 76.69 | 4.73 |
| Total Debt/Mcap(x) | - | 0.09 | 0.20 | 0.12 | 0.15 |
Compare Financial Ratios of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹686.8 Cr | -1.2% | 12.7% | 25.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹410,466.0 Cr | 1.7% | 2% | -0.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹177,298.0 Cr | 0.4% | -2% | 37.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,538.0 Cr | 6% | 10.5% | 13.6% | Stock Analytics | |
| CIPLA | ₹127,140.0 Cr | 6.8% | 4.6% | -0.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,500.0 Cr | 4.2% | 1.3% | -6.7% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | -1.2% |
12.7% |
25.8% |
| SENSEX | -1% |
-3.2% |
1.6% |
You may also like the below Video Courses
